Table 5 The effects on steatosis of cumulative exposure duration to specific antiretroviral medication in 184 HIV-HCV coinfected patients according to the genotype

Antiretrovirals

Cumulative exposure duration (per 1year increase)

Adjusted OR (95% CI)

p

Cumulative exposure duration (per 1year increase)

Adjusted OR (95% CI)

p

Cumulative exposure duration (per 1year increase)

Adjusted OR (95% CI)

p

Nucleoside reverse transcriptase inhibitors

1.05 (0.96-1.16)

0.30

1.07 (0.85-1.35)

0.55

1.03 (0.92-1.15)

0.64

zidovudine

1.03 (0.91-1.16)

0.65

1.01 (0.81-1.27)

0.92

1.00 (0.86-1.17)

0.98

lamivudine

1.01 (0.88-1.17)

0.84

0.99 (0.75-1.32)

0.97

0.99 (0.84-1.17)

0.92

stavudine

1.05 (0.90-1.24)

0.54

1.16 (0.81-1.68)

0.41

0.99 (0.81-1.22)

0.94

didanosine

1.04 (0.85-1.27)

0.70

1.08 (0.64-1.81)

0.77

1.04 (0.83-1.29)

0.75

zalcitabine

1.50 (0.68-3.34)

0.31

NE

1.35 (0.57-3.16)

0.49

tenofovir

1.19 (0.69-2.07)

0.53

0.29 (0.03-2.49)

0.26

1.46 (0.80-2.66)

0.22

abacavir

0.98 (0.69-1.41)

0.94

1.14 (0.54-2.41)

0.73

0.88 (0.56-1.41)

0.61

Protease inhibitors

1.06 (0.90-1.25)

0.50

1.14 (0.82-1.59)

0.44

0.98 (0.80-1.21)

0.87

ritonavir

0.96 (0.71-1.28)

0.76

0.88 (0.45-1.74)

0.72

1.00 (0.71-1.40)

0.98

indinavir

1.14 (0.87-1.47)

0.34

NE

0.89 (0.63-1.25)

0.50

nelfinavir

1.12 (0.79-1.59)

0.54

1.06 (0.63-1.76)

0.83

1.11 (0.66-1.87)

0.68

saquinavir

0.72 (0.45-1.14)

0.16

0.67 (0.33-1.36)

0.26

0.54 (0.25-1.19)

0.13

lopinavir-ritonavir

0.86 (0.54-1.37)

0.52

0.90 (0.13-6.28)

0.92

0.89 (0.54-1.46)

0.64

atazanavir

0.99 (0.35-2.81)

0.98

NE

1.53 (0.43-5.47)

0.51

Non-nucleoside reverse transcriptase inhibitors

1.17 (0.88-1.55)

0.27

1.04 (0.60-1.82)

0.89

1.25 (0.90-1.75)

0.18

efavirenz

1.19 (0.88-1.63)

0.26

1.08 (0.56-2.09)

0.82

1.28 (0.89-1.83)

0.18

nevirapine

1.24 (0.77-2.00)

0.36

0.47 (0.19-1.20)

0.57

1.18 (0.67-2.08)

0.56